

AstraZeneca Pharma India Limited

Familiarisation Programmes for Independent Directors

Preamble

Regulation 25(7) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 inter-alia stipulates that the company shall familiarise the Independent Directors with the Company, their roles, rights, responsibilities in the Company, nature of the industry in which the Company operates, business model of the Company, etc., through various programmes.

Overview of the Familiarisation process

All the Independent Directors of the Company are aware and further updated about their roles, rights, responsibilities in the Company. A Directors' kit containing information about the Company, Organisation Structure, Product Profile, Memorandum and Articles of Association, Annual Reports for previous 3 years, etc., is handed over to the new director, upon joining the Board. The appointment letter issued to Independent Directors inter alia sets out the expectation of the Board from the appointed director, their fiduciary duties and the accompanying liabilities that come with the appointment as a director of the Company.

Independent Directors are provided with necessary documents/brochures, reports and internal policies to enable them to familiarize with the Company's procedures and practices.

Periodic presentations are made at the meetings of the Board and Committee on business and performance updates of the Company, prevailing business environment in the country, industry specific updates, business strategy and risks involved.

Each Director of the Company has complete access to any information relating to the Company. Independent Directors have the freedom to interact with the Company's Management and to seek information / document for enabling a good understanding of the Company, its various operations and the industry segments of which it is a part.

Details of Familiarisation Programme to the Independent Directors during the financial year 2025-26 included the following –

Number of Directors	Number of Programmes	Hours
3	12 (Involving various aspects including Science, Therapy area updates, patient centricity, regulatory updates (SEBI, Transfer Pricing, Uniform Code for Pharmaceutical Marketing Practices etc.), factory operations, business and strategy, Listing Regulations/Company Law/CSR, Business Responsibility and Sustainability Reporting and other strategic projects related updates).	9.05 hours